Cargando…
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
BACKGROUND: To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. METHODS: We studied 200 consecutive patients who received LDR-brachytherapy between July 2004...
Autores principales: | Tanaka, Nobumichi, Asakawa, Isao, Fujimoto, Kiyohide, Anai, Satoshi, Hirayama, Akihide, Hasegawa, Masatoshi, Konishi, Noboru, Hirao, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487947/ https://www.ncbi.nlm.nih.gov/pubmed/22974428 http://dx.doi.org/10.1186/1471-2490-12-28 |
Ejemplares similares
-
Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018) -
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013) -
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017) -
Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020) -
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)